Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | KMT2A - MLLT3 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | E7107 + MS023 | Preclinical - Cell culture | Actionable | In a preclinical study, MS023 and E7107 synergistically inhibited survival of murine KMT2A-MLLT3 (reported as MLL-AF9)-driven acute myeloid leukemia cells in culture, regardless of SRSF2 mutation status (PMID: 31408619). | 31408619 | |
KMT2A - MLLT3 | acute myeloid leukemia | predicted - sensitive | CYC065 | Preclinical - Cell culture | Actionable | In a preclinical study, an acute myeloid leukemia cell line harboring KMT2A-MLLT3 was sensitive to treatment with CYC065 (Fadraciclib) in culture (PMID: 32645016). | 32645016 | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | GSK3203591 + MS023 | Preclinical - Cell culture | Actionable | In a preclinical study, MS023 and GSK3203591 synergistically inhibited survival of murine KMT2A-MLLT3 (reported as MLL-AF9)-driven acute myeloid leukemia (AML) cells and human AML cell lines harboring KMT2A-MLLT3 in culture (PMID: 31408619). | 31408619 | |
KMT2A - MLLT3 | leukemia | sensitive | IRAK1/4 | Preclinical | Actionable | In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413). | 28065413 | |
KMT2A - MLLT3 | acute myeloid leukemia | not applicable | N/A | Guideline | Prognostic | KMT2A-MLLT3 fusions are associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org). | detail... | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | MI-503 | Preclinical - Patient cell culture | Actionable | In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia (AML) cell line and primary AML samples harboring KMT2A-MLLT3 (MLL-AF9) in culture (PMID: 25817203). | 25817203 | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Tretinoin in acute myeloid leukemia cells harboring a KMT2A-MLLT3 fusion induced expression of myeloid differentiation markers, CD11b and PU.1, and resulted in growth inhibition, and in a murine cell model resulted in upregulation of Mac-1 and C/EBPalpha and growth inhibition in culture (PMID: 23063977). | 23063977 | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | Dinaciclib | Preclinical | Actionable | In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013). | 26627013 | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | Decitabine + Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, combination of Tretinoin and Dacogen (decitabine) in acute myeloid leukemia cells harboring KMT2A-MLLT3 resulted in significant growth inhibition, and greatly induced myeloid differentiation as indicated by CD11b and C/EBPalpha expression, and downregulation of c-Myc, and in a murine cell model, resulted in greater upregulation of C/EBPalpha and growth inhibition, and increased apoptosis compared to Tretinoin alone in culture (PMID: 23063977). | 23063977 | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | E7107 + GSK3203591 | Preclinical - Cell culture | Actionable | In a preclinical study, E7107 and GSK3203591 synergistically inhibited survival of murine KMT2A-MLLT3 (reported as MLL-AF9)-driven acute myeloid leukemia cells in culture, regardless of SRSF2 mutation status (PMID: 31408619). | 31408619 | |
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | I-BET151 + SGC0946 | Preclinical - Patient cell culture | Actionable | In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture, and prolonged survival in animal models of mouse KMT2A-MLLT3-positive leukemia (PMID: 27294782). | 27294782 | |
KMT2A - MLLT3 | leukemia | sensitive | MI-503 | Preclinical | Actionable | In a preclinical study, MI-503 reduced progression and improved survival of a mouse leukemia model expressing KMT2A-MLLT3 (MLL-AF9) (PMID: 25817203). | 25817203 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04659616 | Phase I | Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |